Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Check Out What Whales Are Doing With LLY

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter

Dow Jones Rallies; Twitter Plunges After Elon Musk Says Deal 'On Hold'

Dow Jones Rallies; Twitter Plunges After Elon Musk Says Deal 'On Hold'

The Dow Jones Industrial Average rallied 250 points Friday. Twitter plunged after Elon Musk tweeted the deal is "temporarily on hold."

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Futures Extend Stock Market Sell-Off; This Should Worry Investors

The stock market tumbled Wednesday on a hot inflation report. A lack of investor fear suggests no market bottom yet.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

Investors Business Daily

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

inkl

Read news from The Economist, FT, and more,
with one subscription

Weight loss: Weekly jab tricks body into feeling full and causes 24kg drop

Weight loss: Weekly jab tricks body into feeling full and causes 24kg drop

Participants in the trial lost an average of 22.5 per cent of their body weight. This is more than twice the normal effectiveness of such treatments and could be an alternative to surgery for people living with obesity.

Dow Jones Futures Tumble As Market Correction Extends Losses; Why Apple Is An 'Absolute Loser'

Dow Jones Futures Tumble As Market Correction Extends Losses; Why Apple Is An 'Absolute Loser'

The market correction suffered a violent sell-off late in the week. Apple is a relative winner but an absolute loser.

Investors Business Daily

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Investors Business Daily

These Are Some Top-Performing Stocks To Watch With Outstanding Relative Strength

These Are Some Top-Performing Stocks To Watch With Outstanding Relative Strength

Heavy demand for pesticides and fertilizers has led to strength in IBD's agricultural chemicals industry group.

Investors Business Daily

Tesla, Lilly, Microsoft Fight Sell-Off As Indexes Search For Bottom

Tesla, Lilly, Microsoft Fight Sell-Off As Indexes Search For Bottom

With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.

Investors Business Daily

Mower, co-inventor of implantable defibrillator, dies at 89

Mower, co-inventor of implantable defibrillator, dies at 89

A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died

The Independent UK

Analyst Ratings for Eli Lilly

Analyst Ratings for Eli Lilly

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

Investors Business Daily

Dow Jones Falls, Nasdaq Skids On Amazon, AbbVie; Tesla Rises On Elon Musk Move

Stocks fell Friday as Amazon and AbbVie tumbled on earnings. Elon Musk disclosed Tesla stock sales.

Eli Lilly Whale Trades For April 28

Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845.

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Get all your
news in one place.

100’s of premium titles.
One news app.

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.

Investors Business Daily

Here We Go Again: Stock Market Indexes Fade; Meta Platforms Soars, But GDP Falls In Q1

While earnings were mainly higher, the U.S. economy shrank in the first quarter.

Investors Business Daily

Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

Eli Lilly topped first-quarter expectations and raised its sales outlook for 2022, prodding LLY stock to pop Thursday.

Stock Market Today - 4/28: Stocks Bounce Back, Tech Boost; GDP Disappoints, Apple In Focus

The Dow finishes up 600 points as the tech sector helps markets rebound from heavy losses.

Eli Lilly: Q1 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

Eli Lilly Stock Leaps As Trulicity Sales Drive Q1 Earnings Beat, Obesity Drug Trial Data

"We are well-positioned to help address health challenges in areas of significant unmet medical need, such as obesity, Alzheimer's disease and cancer," said CEO David Ricks.

1 … 27 28 29 30

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

247,908 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play